No data to show
XKRX
085660
Market cap466mUSD
Jun 12, Last price
11,380.00KRW
Name
Chabiotech Co Ltd
Chart & Performance
P/E
—
P/S
0.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.98%
Rev. gr., 5y
14.35%
Revenues
1.05t
+9.55%
Net income
-8.05b
L-4.48%
CFO
-49.55b
L
Earnings
Aug 11, 2025
Profile
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | 1,045,049,021 9.55% | 953,951,423 12.95% | 844,582,867 16.10% | ||||||
Cost of revenue | 933,637,978 | 814,905,632 | 774,198,689 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 111,411,043 | 139,045,792 | 70,384,178 | ||||||
NOPBT Margin | 10.66% | 14.58% | 8.33% | ||||||
Operating Taxes | 8,346,150 | 8,747,841 | (1,643,337) | ||||||
Tax Rate | 7.49% | 6.29% | |||||||
NOPAT | 103,064,893 | 130,297,950 | 72,027,515 | ||||||
Net income | (8,053,909) -4.48% | (8,431,247) -82.27% | (47,542,788) 240.36% | ||||||
Dividends | (1,506,858) | (1,231,216) | |||||||
Dividend yield | 0.13% | 0.17% | |||||||
Proceeds from repurchase of equity | 146,785 | 23,631,759 | 99,653 | ||||||
BB yield | -0.02% | -2.11% | -0.01% | ||||||
| Debt | |||||||||
Debt current | 546,564,990 | 307,890,094 | 66,058,463 | ||||||
Long-term debt | 353,318,360 | 196,148,339 | 334,801,266 | ||||||
Deferred revenue | 26,751,807 | 24,768,188 | 23,575,860 | ||||||
Other long-term liabilities | 146,729,436 | 254,654,772 | 156,044,580 | ||||||
Net debt | 562,543,408 | 155,156,003 | (17,552,919) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (49,546,239) | 13,018,245 | (22,118,668) | ||||||
CAPEX | (93,946,977) | (70,364,519) | (128,871,610) | ||||||
Cash from investing activities | 7,364,501 | (83,720,547) | (74,587,813) | ||||||
Cash from financing activities | 214,040,145 | 66,369,352 | 50,424,598 | ||||||
FCF | (78,407,618) | 81,838,014 | (60,912,371) | ||||||
| Balance | |||||||||
Cash | 353,501,183 | 221,788,943 | 250,626,674 | ||||||
Long term investments | (16,161,241) | 127,093,486 | 167,785,975 | ||||||
Excess cash | 285,087,491 | 301,184,858 | 376,183,505 | ||||||
Stockholders' equity | 483,034,357 | 431,426,035 | 292,689,241 | ||||||
Invested Capital | 999,020,704 | 1,084,207,262 | 898,886,725 | ||||||
ROIC | 9.89% | 13.14% | 8.63% | ||||||
ROCE | 6.48% | 10.02% | 5.89% | ||||||
| EV | |||||||||
Common stock shares outstanding | 56,039 | 57,071 | 56,267 | ||||||
Price | 11,460.00 -41.50% | 19,590.00 50.69% | 13,000.00 -34.84% | ||||||
Market cap | 642,201,611 -42.56% | 1,118,013,681 52.85% | 731,467,061 -32.73% | ||||||
EV | 1,640,187,349 | 1,648,156,601 | 1,074,118,222 | ||||||
EBITDA | 156,420,035 | 176,844,867 | 103,166,299 | ||||||
EV/EBITDA | 10.49 | 9.32 | 10.41 | ||||||
Interest | 37,165,450 | 2,171,811 | 20,867,655 | ||||||
Interest/NOPBT | 33.36% | 1.56% | 29.65% | ||||||